Drug prices and trends for NOVOLOG

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
NOVOLOG 100 UNIT/ML VIAL	00169-7501-11	6.93909	ML	2026-03-18
NOVOLOG MIX 70-30 VIAL	00169-3685-12	6.94190	ML	2026-03-18
NOVOLOG PENFILL 100 UNIT/ML	00169-3303-12	8.57065	ML	2026-03-18
NOVOLOG MIX 70-30 FLEXPEN	00169-3696-19	8.94500	ML	2026-03-18
NOVOLOG 100 UNIT/ML FLEXPEN	00169-6339-10	8.93799	ML	2026-03-18
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 12, 2026

Market Position and Overview of NovoLog

NovoLog (insulin aspart) is an ultra-fast-acting insulin marketed by Novo Nordisk. It is designed for rapid glucose control in diabetic patients, with a typical onset within 15 minutes, peak at one to two hours, and duration around three to five hours.

The drug competes primarily with rapid-acting insulins such as Eli Lilly’s Humalog (insulin lispro) and Sanofi’s Apidra (insulin glulisine). NovoLog's market share is significant in the insulin segment, with a global revenue estimated at approximately $1.3 billion in 2022, representing about 8% of the total insulin market.

Market Dynamics and Adoption Drivers

Key Factors Influencing Market Share:

Efficacy data showing comparable or superior glycemic control.
Patient preference for rapid onset and short duration.
Formulation stability allowing flexible dosing.
Patent protection until at least 2031, with biosimilar competition delayed until then due to Novo Nordisk’s patents.

Influencing Market Trends:

Growing prevalence of diabetes, projected to reach 700 million worldwide by 2045 (IDF, 2021).
Increasing adoption of insulin therapy in Type 2 diabetes.
Heightened focus on patient convenience and adherence driving demand for ultra-fast formulations.
Expansion in emerging markets where insulin adoption is rising.

Regulatory and Patent Landscape:

Original patent held until 2031; biosimilar entry is limited, reducing competitive price pressure.
Ongoing development of biosimilar fast-acting insulin analogs, with several candidates in late-phase clinical trials, could influence pricing post-2031, but shelf-life of NovoLog remains protected until patents expire.

Revenue and Pricing Analysis

Current Price Points:

U.S. retail price: Approx. $275 per 10 mL vial.
Average wholesale price (AWP): $250–$300 per vial.
Cost for a typical patient using 0.5–1 unit/kg per day: ~$7,000–$10,000 annually.

Pricing Trends:

Stable in the U.S. due to patent rights.
Slight reductions observed in European markets owing to formulary negotiations.
No significant price erosion anticipated before 2031 under current patent protections.

Cost-Containment Measures:

Use of biosimilars, despite patent protection, remains limited.
Insurance formularies favor NovoLog’s long-standing formulary position.
Bundle discounts and purchasing agreements further stabilize prices.

Future Price Projections

Short-term (Next 3 Years):

Prices are expected to remain stable, with minor discounts in negotiated markets.
Sales volume growth driven by increasing diabetes prevalence and insulin adoption.

Mid to Long-term (Post-2031):

Biosimilar competition may introduce price reductions of 20–40%, depending on market acceptance.
Price erosion trends for biosimilars in insulin are empirically variable, with some markets experiencing steeper declines due to intense competitive pressure.
NovoLog’s market share could decline if biosimilars gain prominence; however, brand loyalty and existing contracts may mitigate rapid erosion.

Revenue Outlook:

Novo Nordisk projects stable or slightly increasing revenue until 2031.
Post-expiry, revenues could decline by 25–50% absent new formulations or indications.
Expect potential new formulations or delivery methods (e.g., patch pumps, automated insulin delivery systems) to offset volume decline.

Competitive Landscape and Impact on Pricing

Insulin Product	Market Share (2022)	Patent Status	Price Range (USD)	Key Differentiators
NovoLog	~8%	Until 2031	$250–$300/vial	Rapid onset, flexible dosing
Humalog (Lilly)	~7%	Until 2031	$250–$300/vial	Similar profile, extensive formulary presence
Apidra (Sanofi)	~4%	Until 2029*	$250–$300/vial	Slightly faster onset, smaller market share

*Sanofi's patent challenge ongoing, with expiration uncertain.

Biosimilar entries anticipated after 2031 could reshape pricing, with early products already in late-stage trials. The market could see price drops of 20–40%, with variations depending on market access policies.

Key Drivers for Future Pricing and Market Share

Regulatory approvals of biosimilar insulins: Early approval could accelerate price reductions.
Manufacturing and distribution efficiencies: Lower costs could lead to more competitive pricing.
Market penetration by biosimilars: May restrict NovoLog’s volume growth and pricing power.
Development of novel formulations: Extended half-life insulins and insulin delivery innovations could influence future market dynamics.

Key Takeaways

NovoLog remains a leading ultra-fast insulin with a stable patent portfolio until 2031.
Market share is protected by current patent rights, with limited biosimilar competition.
Prices are stable domestically, with minor pressures in some regions.
Post-2031, biosimilar competition could reduce prices by up to 40%.
The insulin market is expanding due to global diabetes prevalence, sustaining demand for NovoLog until biosimilar entries.

Frequently Asked Questions

What is the primary competitive advantage of NovoLog? Its rapid onset and short duration support tight glucose control and flexible dosing.
When will biosimilar competitors likely enter the market? After 2031, unless patent challenges succeed earlier, with biosimilars already in late-stage clinical trials for similar insulins.
How are insulin prices trending globally? Prices are stable in mature markets like the U.S. and Europe until patent expiration; emerging markets experience more volatility.
What factors could influence NovoLog’s market share before patent expiry? Formulary substitutions, patient preference, and provider prescribing habits.
What impact will biosimilar entry have on insulin pricing? Expected to cause a 20–40% reduction in product prices depending on market acceptance and regulatory approvals.

Citations:

[1] International Diabetes Federation. IDF Diabetes Atlas, 2021.

[2] IQVIA. 2022 Global Life Sciences Data.

[3] Novo Nordisk Annual Reports, 2022.

[4] Sanofi. Apidra Product Info.

[5] Eli Lilly. Humalog Product Info.

Drug Price Trends for NOVOLOG

Average Pharmacy Cost for NOVOLOG

NOVOLOG Market Analysis and Financial Projection